Programmed cell death 1 - Revision history

Michael: /* IHC */

2016-11-23T17:51:50Z

IHC

← Older revision		Revision as of 17:51, 23 November 2016
Line 37:		Line 37:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	!Clone		!Clone
	!~~Platform~~		!IHC platform
	!Associated drug		!Associated drug
	!Testing required		!Testing required

Michael: /* IHC */ platform

2016-11-23T17:44:33Z

IHC: platform

← Older revision		Revision as of 17:44, 23 November 2016
Line 36:		Line 36:
	<center>		<center>
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	!Clone		!Clone
			!Platform
	!Associated drug		!Associated drug
	!Testing required		!Testing required
	\|-		\|-
	\| 28-8		\| 28-8
			\| Dako
	\| Nivolumab<ref>{{Cite journal \| last1 = Borghaei \| first1 = H. \| last2 = Paz-Ares \| first2 = L. \| last3 = Horn \| first3 = L. \| last4 = Spigel \| first4 = DR. \| last5 = Steins \| first5 = M. \| last6 = Ready \| first6 = NE. \| last7 = Chow \| first7 = LQ. \| last8 = Vokes \| first8 = EE. \| last9 = Felip \| first9 = E. \| title = Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. \| journal = N Engl J Med \| volume = 373 \| issue = 17 \| pages = 1627-39 \| month = Oct \| year = 2015 \| doi = 10.1056/NEJMoa1507643 \| PMID = 26412456 }}</ref>		\| Nivolumab<ref>{{Cite journal \| last1 = Borghaei \| first1 = H. \| last2 = Paz-Ares \| first2 = L. \| last3 = Horn \| first3 = L. \| last4 = Spigel \| first4 = DR. \| last5 = Steins \| first5 = M. \| last6 = Ready \| first6 = NE. \| last7 = Chow \| first7 = LQ. \| last8 = Vokes \| first8 = EE. \| last9 = Felip \| first9 = E. \| title = Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. \| journal = N Engl J Med \| volume = 373 \| issue = 17 \| pages = 1627-39 \| month = Oct \| year = 2015 \| doi = 10.1056/NEJMoa1507643 \| PMID = 26412456 }}</ref>
	\| no testing for squamous carcinoma, pending further information for non-squamous		\| no testing for squamous carcinoma, pending further information for non-squamous
	\|-		\|-
	\| 22C3		\| 22C3
			\| Dako
	\| Pembrolizumab<ref>{{Cite journal \| last1 = Garon \| first1 = EB. \| last2 = Rizvi \| first2 = NA. \| last3 = Hui \| first3 = R. \| last4 = Leighl \| first4 = N. \| last5 = Balmanoukian \| first5 = AS. \| last6 = Eder \| first6 = JP. \| last7 = Patnaik \| first7 = A. \| last8 = Aggarwal \| first8 = C. \| last9 = Gubens \| first9 = M. \| title = Pembrolizumab for the treatment of non-small-cell lung cancer. \| journal = N Engl J Med \| volume = 372 \| issue = 21 \| pages = 2018-28 \| month = May \| year = 2015 \| doi = 10.1056/NEJMoa1501824 \| PMID = 25891174 }}</ref>		\| Pembrolizumab<ref>{{Cite journal \| last1 = Garon \| first1 = EB. \| last2 = Rizvi \| first2 = NA. \| last3 = Hui \| first3 = R. \| last4 = Leighl \| first4 = N. \| last5 = Balmanoukian \| first5 = AS. \| last6 = Eder \| first6 = JP. \| last7 = Patnaik \| first7 = A. \| last8 = Aggarwal \| first8 = C. \| last9 = Gubens \| first9 = M. \| title = Pembrolizumab for the treatment of non-small-cell lung cancer. \| journal = N Engl J Med \| volume = 372 \| issue = 21 \| pages = 2018-28 \| month = May \| year = 2015 \| doi = 10.1056/NEJMoa1501824 \| PMID = 25891174 }}</ref>
	\| testing required		\| testing required
	\|-		\|-
	\| SP142		\| SP142
			\| Ventana
	\| Atezolizumab<ref name=pmid26970723>{{Cite journal \| last1 = Fehrenbacher \| first1 = L. \| last2 = Spira \| first2 = A. \| last3 = Ballinger \| first3 = M. \| last4 = Kowanetz \| first4 = M. \| last5 = Vansteenkiste \| first5 = J. \| last6 = Mazieres \| first6 = J. \| last7 = Park \| first7 = K. \| last8 = Smith \| first8 = D. \| last9 = Artal-Cortes \| first9 = A. \| title = Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. \| journal = Lancet \| volume = 387 \| issue = 10030 \| pages = 1837-46 \| month = Apr \| year = 2016 \| doi = 10.1016/S0140-6736(16)00587-0 \| PMID = 26970723 }}</ref>		\| Atezolizumab<ref name=pmid26970723>{{Cite journal \| last1 = Fehrenbacher \| first1 = L. \| last2 = Spira \| first2 = A. \| last3 = Ballinger \| first3 = M. \| last4 = Kowanetz \| first4 = M. \| last5 = Vansteenkiste \| first5 = J. \| last6 = Mazieres \| first6 = J. \| last7 = Park \| first7 = K. \| last8 = Smith \| first8 = D. \| last9 = Artal-Cortes \| first9 = A. \| title = Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. \| journal = Lancet \| volume = 387 \| issue = 10030 \| pages = 1837-46 \| month = Apr \| year = 2016 \| doi = 10.1016/S0140-6736(16)00587-0 \| PMID = 26970723 }}</ref>
	\| testing required		\| testing required
	\|-		\|-
	\| SP263		\| SP263
			\| Ventana
	\| Durvalumab		\| Durvalumab
	\| testing likely required		\| testing likely required

Michael: /* Drugs */

2016-07-10T19:58:39Z

Drugs

← Older revision		Revision as of 19:58, 10 July 2016
Line 28:		Line 28:
	*Avelumab.		*Avelumab.

	Uncertain whether it binds PD-L1:		Uncertain whether it binds PD-1:
	*Pidilizumab.		*Pidilizumab.

Michael: /* IHC */

2016-07-10T19:57:47Z

IHC

← Older revision		Revision as of 19:57, 10 July 2016
Line 32:		Line 32:

	==IHC==		==IHC==
	*There is no standard ~~PD-1~~ antibody.		*There is no standard antibody.
	*Currently, each drug company has its own clone. Whether the antibodies are interchangeable is a subject of study.		*Currently, each drug company has its own clone. Whether the antibodies are interchangeable is a subject of study.
	<center>		<center>

Michael: /* IHC */

2016-07-10T19:52:20Z

IHC

← Older revision		Revision as of 19:52, 10 July 2016
Line 42:		Line 42:
	\| 28-8		\| 28-8
	\| Nivolumab<ref>{{Cite journal \| last1 = Borghaei \| first1 = H. \| last2 = Paz-Ares \| first2 = L. \| last3 = Horn \| first3 = L. \| last4 = Spigel \| first4 = DR. \| last5 = Steins \| first5 = M. \| last6 = Ready \| first6 = NE. \| last7 = Chow \| first7 = LQ. \| last8 = Vokes \| first8 = EE. \| last9 = Felip \| first9 = E. \| title = Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. \| journal = N Engl J Med \| volume = 373 \| issue = 17 \| pages = 1627-39 \| month = Oct \| year = 2015 \| doi = 10.1056/NEJMoa1507643 \| PMID = 26412456 }}</ref>		\| Nivolumab<ref>{{Cite journal \| last1 = Borghaei \| first1 = H. \| last2 = Paz-Ares \| first2 = L. \| last3 = Horn \| first3 = L. \| last4 = Spigel \| first4 = DR. \| last5 = Steins \| first5 = M. \| last6 = Ready \| first6 = NE. \| last7 = Chow \| first7 = LQ. \| last8 = Vokes \| first8 = EE. \| last9 = Felip \| first9 = E. \| title = Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. \| journal = N Engl J Med \| volume = 373 \| issue = 17 \| pages = 1627-39 \| month = Oct \| year = 2015 \| doi = 10.1056/NEJMoa1507643 \| PMID = 26412456 }}</ref>
	\| no testing for squamous carcinoma, ~~<br>~~pending further information for non-squamous		\| no testing for squamous carcinoma, pending further information for non-squamous
	\|-		\|-
	\| 22C3		\| 22C3

Michael: /* IHC */

2016-07-10T19:51:20Z

IHC

← Older revision		Revision as of 19:51, 10 July 2016
Line 34:		Line 34:
	*There is no standard PD-1 antibody.		*There is no standard PD-1 antibody.
	*Currently, each drug company has its own clone. Whether the antibodies are interchangeable is a subject of study.		*Currently, each drug company has its own clone. Whether the antibodies are interchangeable is a subject of study.
			<center>
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	!Clone		!Clone
Line 56:		Line 56:
	\| testing likely required		\| testing likely required
	\|}		\|}
			</center>

	==See also==		==See also==

Michael: /* IHC */

2016-07-10T19:50:51Z

IHC

← Older revision		Revision as of 19:50, 10 July 2016
Line 42:		Line 42:
	\| 28-8		\| 28-8
	\| Nivolumab<ref>{{Cite journal \| last1 = Borghaei \| first1 = H. \| last2 = Paz-Ares \| first2 = L. \| last3 = Horn \| first3 = L. \| last4 = Spigel \| first4 = DR. \| last5 = Steins \| first5 = M. \| last6 = Ready \| first6 = NE. \| last7 = Chow \| first7 = LQ. \| last8 = Vokes \| first8 = EE. \| last9 = Felip \| first9 = E. \| title = Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. \| journal = N Engl J Med \| volume = 373 \| issue = 17 \| pages = 1627-39 \| month = Oct \| year = 2015 \| doi = 10.1056/NEJMoa1507643 \| PMID = 26412456 }}</ref>		\| Nivolumab<ref>{{Cite journal \| last1 = Borghaei \| first1 = H. \| last2 = Paz-Ares \| first2 = L. \| last3 = Horn \| first3 = L. \| last4 = Spigel \| first4 = DR. \| last5 = Steins \| first5 = M. \| last6 = Ready \| first6 = NE. \| last7 = Chow \| first7 = LQ. \| last8 = Vokes \| first8 = EE. \| last9 = Felip \| first9 = E. \| title = Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. \| journal = N Engl J Med \| volume = 373 \| issue = 17 \| pages = 1627-39 \| month = Oct \| year = 2015 \| doi = 10.1056/NEJMoa1507643 \| PMID = 26412456 }}</ref>
	\| no testing for squamous carcinoma, pending further information for non-squamous		\| no testing for squamous carcinoma, <br>pending further information for non-squamous
	\|-		\|-
	\| 22C3		\| 22C3

Michael: /* IHC */

2016-07-10T19:49:55Z

IHC

← Older revision		Revision as of 19:49, 10 July 2016
Line 32:		Line 32:

	==IHC==		==IHC==
	*There is no standard PD-1 antibody. ~~Each~~ drug company has its own clone. Whether the antibodies are interchangeable is a subject of study.		*There is no standard PD-1 antibody.
			*Currently, each drug company has its own clone. Whether the antibodies are interchangeable is a subject of study.

	{\| class="wikitable sortable"		{\| class="wikitable sortable"

Michael: /* Clones */

2016-07-10T19:47:57Z

Clones

← Older revision		Revision as of 19:47, 10 July 2016
Line 34:		Line 34:
	*There is no standard PD-1 antibody. Each drug company has its own clone. Whether the antibodies are interchangeable is a subject of study.		*There is no standard PD-1 antibody. Each drug company has its own clone. Whether the antibodies are interchangeable is a subject of study.

	=~~==Clones===~~		{\| class="wikitable sortable"
	*Nivolumab: 28-8~~: provides prognostic inflammation, may benefit without staining.~~<ref>{{Cite journal \| last1 = Borghaei \| first1 = H. \| last2 = Paz-Ares \| first2 = L. \| last3 = Horn \| first3 = L. \| last4 = Spigel \| first4 = DR. \| last5 = Steins \| first5 = M. \| last6 = Ready \| first6 = NE. \| last7 = Chow \| first7 = LQ. \| last8 = Vokes \| first8 = EE. \| last9 = Felip \| first9 = E. \| title = Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. \| journal = N Engl J Med \| volume = 373 \| issue = 17 \| pages = 1627-39 \| month = Oct \| year = 2015 \| doi = 10.1056/NEJMoa1507643 \| PMID = 26412456 }}</ref> No testing for squamous carcinoma~~. Pending~~ further information for non-squamous ~~needing staining.~~		!Clone
			!Associated drug
	*Pembrolizumab~~: 22C3:~~<ref>{{Cite journal \| last1 = Garon \| first1 = EB. \| last2 = Rizvi \| first2 = NA. \| last3 = Hui \| first3 = R. \| last4 = Leighl \| first4 = N. \| last5 = Balmanoukian \| first5 = AS. \| last6 = Eder \| first6 = JP. \| last7 = Patnaik \| first7 = A. \| last8 = Aggarwal \| first8 = C. \| last9 = Gubens \| first9 = M. \| title = Pembrolizumab for the treatment of non-small-cell lung cancer. \| journal = N Engl J Med \| volume = 372 \| issue = 21 \| pages = 2018-28 \| month = May \| year = 2015 \| doi = 10.1056/NEJMoa1501824 \| PMID = 25891174 }}</ref> testing required.		!Testing required
			\|-
	*Atezolizumab:<ref name=pmid26970723>{{Cite journal \| last1 = Fehrenbacher \| first1 = L. \| last2 = Spira \| first2 = A. \| last3 = Ballinger \| first3 = M. \| last4 = Kowanetz \| first4 = M. \| last5 = Vansteenkiste \| first5 = J. \| last6 = Mazieres \| first6 = J. \| last7 = Park \| first7 = K. \| last8 = Smith \| first8 = D. \| last9 = Artal-Cortes \| first9 = A. \| title = Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. \| journal = Lancet \| volume = 387 \| issue = 10030 \| pages = 1837-46 \| month = Apr \| year = 2016 \| doi = 10.1016/S0140-6736(16)00587-0 \| PMID = 26970723 }}</ref> ~~SP142:{{fact}}~~ testing required.		\| 28-8
			\| Nivolumab<ref>{{Cite journal \| last1 = Borghaei \| first1 = H. \| last2 = Paz-Ares \| first2 = L. \| last3 = Horn \| first3 = L. \| last4 = Spigel \| first4 = DR. \| last5 = Steins \| first5 = M. \| last6 = Ready \| first6 = NE. \| last7 = Chow \| first7 = LQ. \| last8 = Vokes \| first8 = EE. \| last9 = Felip \| first9 = E. \| title = Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. \| journal = N Engl J Med \| volume = 373 \| issue = 17 \| pages = 1627-39 \| month = Oct \| year = 2015 \| doi = 10.1056/NEJMoa1507643 \| PMID = 26412456 }}</ref>
	*Durvalumab~~: SP263:{{fact}}~~ testing likely required.		\| no testing for squamous carcinoma, pending further information for non-squamous
			\|-
			\| 22C3
			\| Pembrolizumab<ref>{{Cite journal \| last1 = Garon \| first1 = EB. \| last2 = Rizvi \| first2 = NA. \| last3 = Hui \| first3 = R. \| last4 = Leighl \| first4 = N. \| last5 = Balmanoukian \| first5 = AS. \| last6 = Eder \| first6 = JP. \| last7 = Patnaik \| first7 = A. \| last8 = Aggarwal \| first8 = C. \| last9 = Gubens \| first9 = M. \| title = Pembrolizumab for the treatment of non-small-cell lung cancer. \| journal = N Engl J Med \| volume = 372 \| issue = 21 \| pages = 2018-28 \| month = May \| year = 2015 \| doi = 10.1056/NEJMoa1501824 \| PMID = 25891174 }}</ref>
			\| testing required
			\|-
			\| SP142
			\| Atezolizumab<ref name=pmid26970723>{{Cite journal \| last1 = Fehrenbacher \| first1 = L. \| last2 = Spira \| first2 = A. \| last3 = Ballinger \| first3 = M. \| last4 = Kowanetz \| first4 = M. \| last5 = Vansteenkiste \| first5 = J. \| last6 = Mazieres \| first6 = J. \| last7 = Park \| first7 = K. \| last8 = Smith \| first8 = D. \| last9 = Artal-Cortes \| first9 = A. \| title = Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. \| journal = Lancet \| volume = 387 \| issue = 10030 \| pages = 1837-46 \| month = Apr \| year = 2016 \| doi = 10.1016/S0140-6736(16)00587-0 \| PMID = 26970723 }}</ref>
			\| testing required
			\|-
			\| SP263
			\| Durvalumab
			\| testing likely required
			\|}

	==See also==		==See also==

Michael: /* IHC */

2016-07-10T19:42:50Z

IHC

← Older revision		Revision as of 19:42, 10 July 2016
Line 32:		Line 32:

	==IHC==		==IHC==
	*There is no standard PD-1 antibody~~; each~~ drug company has its own clone.		*There is no standard PD-1 antibody. Each drug company has its own clone. Whether the antibodies are interchangeable is a subject of study.

	===Clones===		===Clones===